Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Parkinson's Disease

  Free Subscription


10.04.2017

1 Ann Pharmacother
1 J Neural Transm (Vienna)
1 J Neurochem
1 J Neuropsychol
7 Mov Disord
1 Neurobiol Dis
2 Neurosci Lett
1 PLoS Biol
3 PLoS One
1 Proc Natl Acad Sci U S A
1 Science


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Pharmacother

  1. WILBY KJ, Johnson EG, Johnson HE, Ensom MH, et al
    Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Ann Pharmacother. 2017 Apr 1:1060028017703992. doi: 10.1177/1060028017703992.
    PubMed     Text format     Abstract available


    J Neural Transm (Vienna)

  2. HEIM B, Krismer F, De Marzi R, Seppi K, et al
    Magnetic resonance imaging for the diagnosis of Parkinson's disease.
    J Neural Transm (Vienna). 2017 Apr 4. doi: 10.1007/s00702-017-1717.
    PubMed     Text format     Abstract available


    J Neurochem

  3. AY M, Luo J, Langley M, Jin H, et al
    Molecular Mechanisms Underlying Protective Effects of Quercetin Against Mitochondrial Dysfunction and Progressive Dopaminergic Neurodegeneration in Cell Culture and MitoPark Transgenic Mouse Models of Parkinson's Disease.
    J Neurochem. 2017 Apr 4. doi: 10.1111/jnc.14033.
    PubMed     Text format     Abstract available


    J Neuropsychol

  4. CHONG TT, Bonnelle V, Veromann KR, Juurmaa J, et al
    Dissociation of reward and effort sensitivity in methcathinone-induced Parkinsonism.
    J Neuropsychol. 2017 Apr 5. doi: 10.1111/jnp.12122.
    PubMed     Text format     Abstract available


    Mov Disord

  5. LIU G, Sterling NW, Kong L, Lewis MM, et al
    Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.27006.
    PubMed     Text format     Abstract available

  6. OLANOW CW, Kieburtz K, Leinonen M, Elmer L, et al
    A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26941.
    PubMed     Text format     Abstract available

  7. FOX SH, Metman LV, Nutt JG, Brodsky M, et al
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976.
    PubMed     Text format     Abstract available

  8. LEHERICY S, Vaillancourt DE, Seppi K, Monchi O, et al
    The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26968.
    PubMed     Text format     Abstract available

  9. PONT-SUNYER C, Tolosa E, Caspell-Garcia C, Coffey C, et al
    The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26964.
    PubMed     Text format     Abstract available

  10. ORGAZ L, Gil GB
    Modulating mitochondrial pyruvate carrier: A promising therapeutic target in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26962.
    PubMed     Text format    

  11. YANG X, An R, Xi J, Zheng J, et al
    Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26996.
    PubMed     Text format    


    Neurobiol Dis

  12. LALOUX C, Gouel F, Lachaud C, Timmerman K, et al
    Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?
    Neurobiol Dis. 2017 Mar 28. pii: S0969-9961(17)30061.
    PubMed     Text format     Abstract available


    Neurosci Lett

  13. YANG X, Zheng J, An R, Tian S, et al
    Polymorphism in MIR4697 but not VPS13C, GCH1, or SIPA1L2 is associated with risk of Parkinson's disease in a Han Chinese population.
    Neurosci Lett. 2017 Apr 2. pii: S0304-3940(17)30287.
    PubMed     Text format     Abstract available

  14. LIU H, Liu H, Li T, Cui J, et al
    NR4A2 genetic variation and Parkinson's disease: evidence from a systematic review and meta-analysis.
    Neurosci Lett. 2017 Apr 3. pii: S0304-3940(17)30090.
    PubMed     Text format     Abstract available


    PLoS Biol

  15. DE OLIVEIRA RM, Vicente Miranda H, Francelle L, Pinho R, et al
    Correction: The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease.
    PLoS Biol. 2017;15:e1002601.
    PubMed     Text format     Abstract available


    PLoS One

  16. PATERNITI I, Campolo M, Siracusa R, Cordaro M, et al
    Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson's disease.
    PLoS One. 2017;12:e0174470.
    PubMed     Text format     Abstract available

  17. ROZANI V, Giladi N, El-Ad B, Gurevich T, et al
    Statin adherence and the risk of Parkinson's disease: A population-based cohort study.
    PLoS One. 2017;12:e0175054.
    PubMed     Text format     Abstract available

  18. TRENADO C, Elben S, Friggemann L, Gruhn S, et al
    Correction: Long-Latency Somatosensory Evoked Potentials of the Subthalamic Nucleus in Patients with Parkinson's Disease.
    PLoS One. 2017;12:e0175602.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  19. Editorial Expression of Concern: Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.
    Proc Natl Acad Sci U S A. 2017 Apr 3. pii: 201704295.
    PubMed     Text format    


    Science

  20. JUCKER M, Heikenwalder M
    Immune receptor for pathogenic alpha-synuclein.
    Science. 2016;353:1498-1499.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: